Loading clinical trials...
Loading clinical trials...
Hormonal treatment of gender dysphoria can have repercussions on metabolism, cardiovascular system and fertility and represents à potential oncological risk. According to the recommendations of the Endocrine society. Therefore, initial assessment and follow-up visits are necessary and must be carried out to avoid the apparition of potentially undesirable effects.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
CHRU de Nancy
Nancy, France
Start Date
February 2, 2022
Primary Completion Date
November 1, 2022
Completion Date
January 1, 2023
Last Updated
July 26, 2022
20
ESTIMATED participants
no intervention
OTHER
Lead Sponsor
Central Hospital, Nancy, France
NCT06639763
NCT06439290
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions